Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocatinlimab + TCS/TCI in Moderate-to-severe Atopic Dermatitis (ROCKET-SHUTTLE)
NCT05724199Phase 3Completed
- Sponsor
- Amgen
- Start
- Feb 2023
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of rocatinlimab in atopic dermatitis (AD), sponsored by Amgen. Started Feb 2023; status: completed.
02
Drugs
rocatinlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05724199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05724199.